BTIG Maintains a Hold Rating on Electrocore Llc (ECOR)

By Austin Angelo

In a report released yesterday, Sean Lavin from BTIG maintained a Hold rating on Electrocore Llc (ECORResearch Report). The company’s shares closed last Monday at $1.56, close to its 52-week low of $1.23.

According to, Lavin is a 4-star analyst with an average return of 2.9% and a 52.9% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.

Electrocore Llc has an analyst consensus of Moderate Buy, with a price target consensus of $17.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.99 and a one-year low of $1.23. Currently, Electrocore Llc has an average volume of 235.4K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ECOR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function.